Abstract
Since the earliest descriptions of Alzheimer ’ s disease (AD), the presence of senile plaques (SP) and neurofibrillary tangles (NFT) have been regarded as the typical pathological hallmarks of the disease. Studies over the last twenty years, however, have reported a considerable degree of heterogeneity within the AD phenotype and as a consequence, an overlap between the pathological features of AD not only with normal aging, but also with disorders related to AD. This review discusses: 1) the degree of heterogeneity within AD, 2) the concept of an ‘interface’ between disorders, 3) the nature and degree of the interface between AD and normal aging, vascular dementia (VD), the tauopathies, synucleinopathies, and prion disease, and 4) whether the original status of AD should be retained or whether AD, normal aging, and the related disorders should be regarded as representing a ‘continuum’ of neuropathological change.
Keywords: Alzheimer's disease (AD), brain lesion, continuum, disease heterogeneity, tauopathy, synucleinopathy, prion disease
Current Aging Science
Title: The Interface Between Alzheimers Disease, Normal Aging, and Related Disorders
Volume: 1 Issue: 2
Author(s): R. A. Armstrong
Affiliation:
Keywords: Alzheimer's disease (AD), brain lesion, continuum, disease heterogeneity, tauopathy, synucleinopathy, prion disease
Abstract: Since the earliest descriptions of Alzheimer ’ s disease (AD), the presence of senile plaques (SP) and neurofibrillary tangles (NFT) have been regarded as the typical pathological hallmarks of the disease. Studies over the last twenty years, however, have reported a considerable degree of heterogeneity within the AD phenotype and as a consequence, an overlap between the pathological features of AD not only with normal aging, but also with disorders related to AD. This review discusses: 1) the degree of heterogeneity within AD, 2) the concept of an ‘interface’ between disorders, 3) the nature and degree of the interface between AD and normal aging, vascular dementia (VD), the tauopathies, synucleinopathies, and prion disease, and 4) whether the original status of AD should be retained or whether AD, normal aging, and the related disorders should be regarded as representing a ‘continuum’ of neuropathological change.
Export Options
About this article
Cite this article as:
Armstrong A. R., The Interface Between Alzheimers Disease, Normal Aging, and Related Disorders, Current Aging Science 2008; 1 (2) . https://dx.doi.org/10.2174/1874609810801020122
DOI https://dx.doi.org/10.2174/1874609810801020122 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patent Advances for Neurodegenerative Disorders and its Treatment
Recent Patents on Drug Delivery & Formulation RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy The Effect of Cognitive Remediation Therapy on Social Skills in Institutionalized Elderly Patients with Schizophrenia
Reviews on Recent Clinical Trials α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science Polyphenols: A Diverse Class of Multi-Target Anti-HIV-1 Agents
Current Drug Metabolism Inflammatory Responses in Brain Ischemia
Current Medicinal Chemistry The State of the Art of Pyrazole Derivatives as Monoamine Oxidase Inhibitors and Antidepressant/Anticonvulsant Agents
Current Medicinal Chemistry Anti-α4β1 Integrin Antibodies Attenuated Brain Inflammatory Changes in a Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design Conference Report: 14th International Congress on Amino Acids, Peptides and Proteins, Vienna, Austria, August 3-7, 2015
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: QSAR Models for Computer-Aided Drug Design and Molecular Docking for Disorders of the Central Nervous System and Other Diseases]
Current Topics in Medicinal Chemistry The Underestimated Role of Mechanical Stimuli in Brain Diseases and the Relate d In Vitro Models
Current Pharmaceutical Design HIV Compartmentalization: A Review on a Clinically Important Phenomenon
Current HIV Research Effect of Brain-Derived Neurotrophic Factor (BDNF) Gene Variants on the Therapeutic Response and the Risk for Mood Disorders
Current Pharmacogenomics and Personalized Medicine Early-phase 18F-AV-45 PET Imaging can Detect Crossed Cerebellar Diaschisis Following Carotid Artery Stenosis and Cerebral Hypoperfusion
Current Neurovascular Research LINE-1 Methylation is Associated with an Increased Risk of Ischemic Stroke in Men
Current Neurovascular Research Innovations to Control the Environment for Persons with Movement Disorders: Support in Home Care
Recent Patents on Biomedical Engineering (Discontinued) Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies
Current Pharmaceutical Design